Cost-Effectiveness Analyses of Natalizumab for 1st Line Versus Interferon Beta-1a 44 Mcg in the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis Patients in Brazil

Nov 1, 2013, 00:00
10.1016/j.jval.2013.08.2249
https://www.valueinhealthjournal.com/article/S1098-3015(13)04161-2/fulltext
Title : Cost-Effectiveness Analyses of Natalizumab for 1st Line Versus Interferon Beta-1a 44 Mcg in the Treatment of Highly Active Relapsing-Remitting Multiple Sclerosis Patients in Brazil
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(13)04161-2&doi=10.1016/j.jval.2013.08.2249
First page : A721
Section Title : Disease-Specific Studies
Open access? : No
Section Order : 2061
Categories :
Tags :
Regions :
ViH Article Tags :